Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Exosomal transfer of miR-126 promotes the anti-tumour response in malignant mesothelioma: Role of miR-126 in cancer-stroma communication

F. Monaco, S. Gaetani, F. Alessandrini, A. Tagliabracci, M. Bracci, M. Valentino, J. Neuzil, M. Amati, M. Bovenzi, M. Tomasetti, L. Santarelli,

. 2019 ; 463 (-) : 27-36. [pub] 20190807

Language English Country Ireland

Document type Journal Article

Grant support
NV16-31604A MZ0 CEP Register

MiR-126 has been shown to suppress malignant mesothelioma (MM) by targeting cancer-related genes without inducing toxicity or histopathological changes. Exosomes provide the opportunity to deliver therapeutic cargo to cancer stroma. Here, a tumour stromal model composed of endothelial cells (HUVECs), fibroblasts (IMR-90 cells), non-malignant mesothelial cells (Met-5A cells) and MM cells (H28 and MM-B1 cells) was used. The cells were treated with exosomes from HUVECs carrying endogenous (exo-HUVEC) and enriched miR-126 (exo-HUVECmiR-126), and the uptake/turnover of exosomes; miR-126 distribution within the stroma; and effect of miR-126 on cell signalling, angiogenesis and cell proliferation were evaluated. Based on the sensitivity of MM cells to exo-HUVEC miR-126 treatment, miR-126 was distributed differently across stromal cells. The reduced miR-126 content in fibroblasts in favour of endothelial cells reduced angiogenesis and suppressed cell growth in an miR-126-sensitive environment. Conversely, the accumulation of miR-126 in fibroblasts and the reduced level of miR-126 in endothelial cells induced tube formation in an miR-126-resistant environment via VEGF/EGFL7 upregulation and IRS1-mediated cell proliferation. These findings suggest that transfer of miR-126 via HUVEC-derived exosomes represents a novel strategy to inhibit angiogenesis and cell growth in MM.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023578
003      
CZ-PrNML
005      
20201214130446.0
007      
ta
008      
201125s2019 ie f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.canlet.2019.08.001 $2 doi
035    __
$a (PubMed)31400405
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ie
100    1_
$a Monaco, Federica $u Department of Clinical and Molecular Sciences, Section of Experimental and Occupational Medicine, Polytechnic University of Marche, Via Tronto 10/A, 60126, Ancona, Italy.
245    10
$a Exosomal transfer of miR-126 promotes the anti-tumour response in malignant mesothelioma: Role of miR-126 in cancer-stroma communication / $c F. Monaco, S. Gaetani, F. Alessandrini, A. Tagliabracci, M. Bracci, M. Valentino, J. Neuzil, M. Amati, M. Bovenzi, M. Tomasetti, L. Santarelli,
520    9_
$a MiR-126 has been shown to suppress malignant mesothelioma (MM) by targeting cancer-related genes without inducing toxicity or histopathological changes. Exosomes provide the opportunity to deliver therapeutic cargo to cancer stroma. Here, a tumour stromal model composed of endothelial cells (HUVECs), fibroblasts (IMR-90 cells), non-malignant mesothelial cells (Met-5A cells) and MM cells (H28 and MM-B1 cells) was used. The cells were treated with exosomes from HUVECs carrying endogenous (exo-HUVEC) and enriched miR-126 (exo-HUVECmiR-126), and the uptake/turnover of exosomes; miR-126 distribution within the stroma; and effect of miR-126 on cell signalling, angiogenesis and cell proliferation were evaluated. Based on the sensitivity of MM cells to exo-HUVEC miR-126 treatment, miR-126 was distributed differently across stromal cells. The reduced miR-126 content in fibroblasts in favour of endothelial cells reduced angiogenesis and suppressed cell growth in an miR-126-sensitive environment. Conversely, the accumulation of miR-126 in fibroblasts and the reduced level of miR-126 in endothelial cells induced tube formation in an miR-126-resistant environment via VEGF/EGFL7 upregulation and IRS1-mediated cell proliferation. These findings suggest that transfer of miR-126 via HUVEC-derived exosomes represents a novel strategy to inhibit angiogenesis and cell growth in MM.
650    _2
$a proteiny vázající vápník $x metabolismus $7 D002135
650    _2
$a karcinogeneze $x metabolismus $7 D063646
650    _2
$a mezibuněčná komunikace $x fyziologie $7 D002450
650    _2
$a kultivované buňky $7 D002478
650    _2
$a epidermální růstové faktory $x metabolismus $7 D066255
650    _2
$a exozómy $x metabolismus $7 D055354
650    _2
$a fibroblasty $x metabolismus $7 D005347
650    _2
$a lidé $7 D006801
650    _2
$a nádory plic $x metabolismus $7 D008175
650    _2
$a mezoteliom $x metabolismus $7 D008654
650    _2
$a mikro RNA $x metabolismus $7 D035683
650    _2
$a signální transdukce $x fyziologie $7 D015398
650    _2
$a vaskulární endoteliální růstový faktor A $x metabolismus $7 D042461
655    _2
$a časopisecké články $7 D016428
700    1_
$a Gaetani, Simona $u Department of Clinical and Molecular Sciences, Section of Experimental and Occupational Medicine, Polytechnic University of Marche, Via Tronto 10/A, 60126, Ancona, Italy.
700    1_
$a Alessandrini, Federica $u Department of Biomedical Sciences and Public Health, Section of Legal Medicine, Polytechnic University of Marche, Via Tronto 10/A, 60126, Ancona, Italy.
700    1_
$a Tagliabracci, Adriano $u Department of Biomedical Sciences and Public Health, Section of Legal Medicine, Polytechnic University of Marche, Via Tronto 10/A, 60126, Ancona, Italy.
700    1_
$a Bracci, Massimo $u Department of Clinical and Molecular Sciences, Section of Experimental and Occupational Medicine, Polytechnic University of Marche, Via Tronto 10/A, 60126, Ancona, Italy.
700    1_
$a Valentino, Matteo $u Department of Clinical and Molecular Sciences, Section of Experimental and Occupational Medicine, Polytechnic University of Marche, Via Tronto 10/A, 60126, Ancona, Italy.
700    1_
$a Neuzil, Jiri $u Mitochondria, Apoptosis and Cancer Research Group, School of Medical Science, Griffith University, Southport, 4222, Qld, Australia; Molecular Therapy Group, Institute of Biotechnology, Czech Academy of Sciences, Prague-West, 252 50, Czech Republic.
700    1_
$a Amati, Monica $u Department of Clinical and Molecular Sciences, Section of Experimental and Occupational Medicine, Polytechnic University of Marche, Via Tronto 10/A, 60126, Ancona, Italy.
700    1_
$a Bovenzi, Massimo $u Department of Medical Sciences, University of Trieste, Trieste, Italy.
700    1_
$a Tomasetti, Marco $u Department of Clinical and Molecular Sciences, Section of Experimental and Occupational Medicine, Polytechnic University of Marche, Via Tronto 10/A, 60126, Ancona, Italy. Electronic address: m.tomasetti@staff.univpm.it.
700    1_
$a Santarelli, Lory $u Department of Clinical and Molecular Sciences, Section of Experimental and Occupational Medicine, Polytechnic University of Marche, Via Tronto 10/A, 60126, Ancona, Italy. Electronic address: l.santarelli@univpm.it.
773    0_
$w MED00001044 $t Cancer letters $x 1872-7980 $g Roč. 463, č. - (2019), s. 27-36
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31400405 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214130444 $b ABA008
999    __
$a ok $b bmc $g 1595897 $s 1114254
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 463 $c - $d 27-36 $e 20190807 $i 1872-7980 $m Cancer letters $n Cancer Lett $x MED00001044
GRA    __
$a NV16-31604A $p MZ0
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...